Calendar

About the Event

Diseases in the central nervous system (CNS) are often difficult to treat. Antibody and protein-based therapeutics hold huge promises in CNS disease treatment. Using Alzheimer’s Disease (AD) and GBM as examples, this presentation will discuss the platforms developed by the Texas Therapeutics Institute to increase macromolecule brain entry to combat CNS diseases.

About the Speaker

Zhiqiang An, Ph.D., is an elected fellow of the Society for Industrial Microbiology and Biotechnology (SIMB), the American Academy of Microbiology (ASM), American Association for the Advancement of Science (AAAS), and the National Academy of Inventors (NAI). His laboratory focuses on antibody drug discovery targeting human diseases, advancing five first-in-class drug candidates into clinical trials. More at https://www.uth.edu/imm/labs/antibody-drug-discovery/index.htm

L

 REGISTER